PR agencies warn of ‘race to the bottom’
February 10, 2012Medical Communications HCA, PR
A new survey of PR agencies working in healthcare has highlighted concerns about cost-cutting which they say could lower standards …
Value destruction: pharma has only itself to blame
February 10, 2012R&D productivity
Pharma has only itself to blame for destroying value from its R&D pipeline, according to Andrew Baum, managing director of …
MPs support health and social care integration
February 10, 2012Sales and Marketing NHS, social care
The integration of care services will help improve outcomes for older people and those with disabilities and long-term conditions, according …
Oxford BioMedica makes management change
February 10, 2012Research and Development, Sales and Marketing Oxford BioMedica
Gene-based biopharmaceutical firm Oxford BioMedica has announced that Andrew Wood, chief financial officer, has stepped down from the board of Oxford …
Chiltern welcomes Gastroenterology, Oncology and Pediatric Therapeutic experts to their team
February 9, 2012Research and Development
Chiltern International Limited (Chiltern), a global contract research organization (CRO), announced that Drs. Marcelo Piccirillo and Carlo Lanza have joined …
Doctors, medical education and pharma – the way ahead
February 9, 2012Medical Communications ABPI, ASME, CME, Continuing medical education, GMC, MEP
InPharm CME event Roy Pounder, Andrew Powrie-Smith, Richard Marchant, Roy Lilley, Kieran Walsh and Chuka Nwokolo are all speakers at …
European Medicines Agency and European Food Safety Authority commit to a stronger collaboration
February 9, 2012Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing
The European Medicines Agency (EMA) and the European Food Safety Authority (EFSA) have agreed to work closer together on areas …
Bayer UK/Ireland appoints new chief financial officer
February 9, 2012Business Services, Sales and Marketing Bayer, Ute Bockstegers
Bayer has appointed Ms Ute Bockstegers as chief financial officer and head of business administration and partnering.Ute Bockstegers comes to …
Fate of Merck’s vorapaxar still unclear
February 8, 2012Medical Communications, Sales and Marketing Merck, vorapaxar
Merck & Co’s blood thinner vorapaxar, designed to prevent blood clots and reduce heart attacks, is still causing bleeding in …
New drug discounts should be made transparent
February 8, 2012Medical Communications, Sales and Marketing ABPI, NHS, NICE, access scheme, pricing
Patient access schemes agreed through NICE should be made more transparent. This is according to Paul McManus, a pharmacist and …
GSK posts strong underlying sales growth
February 8, 2012Research and Development, Sales and Marketing Avodart, GSK, R&D, Seretide, Witty, rotarix
GlaxoSmithKline has posted strong underlying growth for 2011, but warns of a tough year ahead. The UK firm saw 4% …
Hospira appoints Richard Davies as chief commercial officer
February 8, 2012Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Hospira, Richard Davies
Hospira has announced Richard Davies as its senior vice president and chief commercial officer. In this role, he will be responsible for …
Breast cancer treatment – the next advances
February 7, 2012Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Afinitor, CDF, Lorena Tonarelli, T-DM1, breast cancer, pertuzumab
When a close member of my family was diagnosed with breast cancer, the doctors didn’t give us much hope. They …
Merck prepares insomnia candidate
February 7, 2012Sales and Marketing Merck, insomnia
Merck is to file its new insomnia drug suvorexant, with US regulators later this year. Suvorexant is an orexin receptor …
Dr Stephen Rosevear joins Cogent as director of Research & Policy
February 7, 2012Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Cogent, Stephen Rosevear
Prior to joining Cogent, Stephen was HMRC’s chief analyst on the corporate real estate market, undertaking tax modeling and policy development for …
Latest content
Five Facts about NHS and primary care
AI in pharma: From lab development to patient impact
